EDTA Chelation Therapy: Lead, Calcium and Blood Vessels
EDTA does not dissolve arterial calcium. It binds lead. Why salt, infusion rate and monitoring decide on safety, and what the evidence honestly supports.
An area of practice focus at ViveCura: Heavy Metal Diagnostics & Chelation Therapy
EDTA is part of my toolkit in heavy metal elimination, one of my areas of practice focus. It matters to me not to oversell or undersell it here. EDTA is not an artery cleaner, but with a proven lead burden it could be a closely monitored building block. You will find the overview of all metals and the diagnostics in the heavy metals pillar.
EDTA infusion solutions are prescription-only medicines. For elimination in cases of a proven lead burden they are provided for under medicinal products law, and availability in Germany is limited and partly runs through single-patient import. For use on the vascular system, that is as heart or artery protection, there is no marketing authorization. That would be off-label use. A physician has to explain this separately beforehand. It also raises questions about cost coverage and liability.
I deliberately do not give any dosages here. They belong in the individual medical decision after diagnostics, not in an article. This text is information on the state of the science, not a treatment recommendation.
Two worlds, nothing in between
If you google EDTA chelation therapy, you find either a miracle promise or a warning. Rarely anything in between. One side shows practice pages talking about "clean arteries." The other side shows consumer portals warning of "quackery." Both poles sound very confident. What I miss in both is the question of what EDTA actually does biologically. That is exactly where I would like to start, without claiming that I have the final answer.
It is precisely this in-between that is the honest answer. EDTA is neither a miracle cure nor a fraud. It is a molecule with a very specific ability and very specific limits. Once you understand what it really does, the decision becomes easier as to whether it is even a topic for you at all.
This article is about EDTA as infusion therapy. Not about the EDTA in the blood collection tube at your family doctor's office. There, EDTA only serves to keep the blood sample from clotting. It is the same substance name, but a completely different context. If you are searching for "EDTA blood tube," you are in the wrong place. If you want to know whether an EDTA infusion can pull lead out of the body and protect the blood vessels, you are exactly right.
The calcium myth: EDTA does not dissolve calcification
Many people who hear about EDTA for the first time share the same train of thought. It sounds logical and is nonetheless wrong. It goes like this: EDTA binds calcium, arterial plaques contain calcium, therefore EDTA dissolves the plaques. A clean three-step logic. It just does not hold up biologically.
Calcified plaques are not a loose calcium coating you could rinse away. They are stably built into the vascular tissue, embedded in connective tissue and cells. An infusion does not simply bind the calcium out of a finished plaque. The mechanism through which EDTA could have any effect on blood vessels at all runs somewhere else entirely.
EDTA does not dissolve calcium. It binds metal. The plausible pathway of action is the removal of lead, which can disrupt vascular function. Lead can lower the availability of nitric oxide and promote oxidative stress in the vessel wall. This is shown above all by animal models, cell experiments and summarizing reviews. In humans, this pathway has not been conclusively proven. Whoever lowers the lead could ease this disruption. That would be something fundamentally different from dissolving calcification.
This difference decides everything. It explains why EDTA could only make sense where relevant lead is actually present in the first place. And it exposes the promise of an "artery cleaner" for what it is: a nice but false shortcut.
Viewed through the toxicology lens, EDTA is a classic chelating agent. The word comes from the Greek "chele," the crab's claw. The molecule encloses a metal ion like a pair of pincers at several points at once and forms a stable ring complex. This complex is water-soluble and is excreted via the kidney. That is the whole magic: a very concrete chemical bond, not a mystical cleansing.
How EDTA binds lead and why it takes patience
Many people imagine lead elimination as a one-time rinse. One infusion, lead gone. But that is not how the body works. Lead distributes across several stores with very different inertia. That explains why a single infusion is never the whole picture.
The pincers close
EDTA grips a lead ion at several binding sites at once and forms a stable, water-soluble ring complex. The bound lead can no longer exert its harmful effect and becomes transportable.
The kidney excretes it
The lead-EDTA complex is released into the urine via the kidney. But the kidney here is not only the exit, it is also the most sensitive organ in the procedure. EDTA can burden kidney function. That is why kidney values must be clarified beforehand and checked during the cycle. In the trials, blood lead fell measurably and clearly under EDTA.
The blood empties first
What circulates in the blood is bound quickly. But blood lead is only the tip. It reflects the most recent exposure, not what has been stored over years.
The bone remains the deep reservoir
The largest part of the body's lead burden is stored in the bone. The dwell time there is reported as years to decades. A longitudinal measurement in occupationally exposed workers found tibia half-lives of about five years in those under 40 and around fourteen years in those over 40 (Brito 2001). From there, lead can slowly migrate back into the blood, a process called redistribution. That is why a single infusion cannot reach the bone reservoir, and a sensible elimination needs several cycles and clinical supervision instead of a quick fix.
Where the lead sits: three stores, three speeds
Schematic representation of relative dwell time, not exact scales. The point: an infusion mainly reaches the blood. The bone lead is the reason why elimination needs time and repetition, and why follow-up monitoring matters more than a single measured value.
Lead is an underestimated vascular risk factor
For EDTA to make any sense for blood vessels, one assumption has to hold: that lead harms the vessels. And precisely here, the data is surprisingly solid. Two large US cohorts from the NHANES program consistently show that even low blood lead levels are linked to increased cardiovascular mortality. Low means: well below the old threshold that was long considered harmless.
A representative US sample was followed for up to twelve years. Even blood lead levels below 10 micrograms per deciliter were associated with increased mortality. For the highest versus the lowest lead tertile, cardiovascular mortality showed a hazard ratio of 1.55.
What this means for you: Even a low lead burden, one that would not stand out in any routine check, can go hand in hand with a higher cardiovascular death risk. Lead is not a fringe topic.
DOI: 10.1161/CIRCULATIONAHA.106.628321The same NHANES basis, median follow-up over 19 years. An increase in blood lead from 1.0 to 6.7 micrograms per deciliter was associated with a cardiovascular mortality HR of 1.70, and for ischemic heart disease even 2.08. Extrapolated, the authors attribute around 256,000 cardiovascular deaths per year in the US to lead exposure.
What this means for you: A seemingly harmless lead burden contributes substantially to cardiovascular deaths at the population level. This is the empirical basis for why lowering lead could be biologically plausible and sensible, when a relevant lead burden is present.
DOI: 10.1016/S2468-2667(18)30025-2Where the lead in your body even comes from, from old water pipes to imported spices, and how a burden shows itself, I have described in the separate article on lead poisoning: sources, symptoms and elimination. Here I stay with the vascular aspect.
Why lead harms blood vessels: the NO pathway, not calcium
If not through calcium, then how? Viewed through the functional and toxicological lens, the damage runs through two closely linked mechanisms: oxidative stress and a disturbed nitric oxide biology. Nitric oxide, NO for short, is the body's own messenger that dilates vessels and keeps them supple. Lead attacks exactly here.
This review summarizes the cellular mechanisms through which lead promotes high blood pressure and vascular disease. Lead increases oxidative stress, lowers NO availability, disrupts the NO signaling pathways, damages the endothelium and favors atherosclerosis and thrombosis.
What this means for you: The damage from lead runs through NO and oxidative stress, not through calcium. This is the mechanistic correction of the popular myth.
DOI: 10.1152/ajpheart.00158.2008This work actually examined whether the substance sildenafil can attenuate a lead-induced vascular disturbance. Sildenafil is prescription-only, and here it served as an experimental intervention in an animal model, not as a treatment suggestion. What is interesting for us is the underlying model: in a rat model and in human endothelial cells, lead went together with lower NO bioavailability and disrupted endothelium-dependent vasodilation. The authors consider oxidative stress the likely mediator, which does not make it proven.
What this means for you: The model supports the mechanism that lead can impair vascular function via the NO pathway. It says nothing about whether lowering lead protects the vessels in humans. Such data show plausibility, they are explicitly not clinical proof of efficacy in humans.
DOI: 10.1111/bcpt.13904This review on the relationship between lead exposure and cardiovascular disease arrives independently at the same picture: chronic low-level lead exposure can trigger high blood pressure, through oxidative stress with a functional NO deficit, increased sympathetic activity and further levers of vascular tone.
What this means for you: A second, independent source supports the NO mechanism. That makes the narrative "lead disrupts NO" more robust than a single finding.
Apostoli P et al. [Lead and cardiopathy]. Med Lav. 2004;95(2):124-32. PMID 15218744This is one view among several, and it is not conclusively proven. But it is consistent across several sources and mechanistically plausible. What can be held onto: if EDTA works on blood vessels, then most likely because it removes lead that disrupts this NO biology. Not because it scrubs away calcification.
The most important safety question: which salt, how fast, how monitored
Before we talk about efficacy, comes safety. And here one finding stands in the foreground. There is no such thing as "the one EDTA." There are two salts that are named almost identically and behave very differently.
The difference is safety-relevant
Both salts carry the name EDTA. The decisive difference is whether calcium is already attached to the molecule. That is exactly what can turn a comparatively controllable agent into a potentially lethal one.
Calcium disodium EDTA already carries calcium. It exchanges the calcium for lead and largely leaves the blood calcium level alone. This is the salt used for lead elimination. This salt is not risk-free either.
Disodium EDTA carries no calcium. Infused quickly, it abruptly binds blood calcium and can trigger life-threatening hypocalcemia with cardiac arrest.
This is not a theoretical worry.
The US health authority CDC documented three deaths during chelation therapy in three states. All three died of cardiac arrest caused by hypocalcemia during chelation therapy. What stands at the center of the discussion of these cases is the confusion of disodium EDTA (Na₂EDTA) with the calcium disodium EDTA intended for lead elimination. Among the documented cases there was also a preschool child. Since then the authority explicitly recommends not using Na₂EDTA for chelation therapy in children at all, and that hospitals check whether they still need to stock Na₂EDTA. The same report states that chelating agents also increase the excretion of other heavy metals and minerals such as zinc.
What this means for you: A single letter in the product name can be life-threatening. The correct salt, correct dosing, a slow infusion rate and electrolyte monitoring therefore belong together. Anyone considering EDTA therapy may ask directly which salt is being used and how monitoring is done.
CDC. Deaths associated with hypocalcemia from chelation therapy. MMWR Morb Mortal Wkly Rep. 2006;55(8):204-7. PMID 16511441One clarification matters here, because it often gets lost. TACT and TACT2 did not use CaNa₂EDTA, but disodium EDTA (Na₂EDTA), infused strictly slowly over several hours and under trial conditions. Under that protocol, no cluster of serious side effects appeared. For plain lead elimination outside such trials, CaNa₂EDTA is considered the safer salt. Na₂EDTA becomes dangerous above all when it is infused quickly or confused with CaNa₂EDTA. So safety here hangs on salt, speed and monitoring at the same time, not on a single letter.
And one more classification I do not want to leave out: even with the right salt and the correct protocol, an EDTA infusion is not a risk-free procedure. It can burden the kidneys, shift the mineral balance, lower blood pressure and, if given too quickly, disturb the calcium level. In the large trials, no cluster of serious side effects appeared under trial conditions, but that only exonerates the trial protocol, not every application in practice. Care can lower the risk, it does not remove it.
What has to be clarified before an EDTA infusion
Kidney. EDTA can burden kidney function. Pre-existing kidney weakness can rule out chelation therapy or at least force close monitoring. Even the TACT trial only enrolled people with a serum creatinine up to 2.0 mg/dL. Kidney values therefore belong to the mandatory program before, during and after a cycle.
Children. The CDC explicitly recommends not using Na₂EDTA for chelation therapy in children. Chelation therapy in childhood belongs exclusively in specialized, toxicologically experienced hands.
Pregnancy and breastfeeding. Chelation therapy mobilizes lead out of the store. Mobilized lead can cross the placenta and pass into breast milk. In pregnancy and breastfeeding, elimination is therefore only conceivable after very careful weighing and under specialized care.
Interactions. EDTA infusions can influence blood sugar, and in people treated with insulin an adjustment may become necessary. Shifts in the calcium level can change the effect of digitalis preparations. Existing anticoagulation, heart failure and blood pressure medication also belong in the conversation beforehand.
The right salt is not a free pass either. Even CaNa₂EDTA can cause calcium and circulatory problems if infused too quickly or without electrolyte monitoring. This list is not a complete product information leaflet. It is meant to show that an EDTA infusion is a medical decision with preparation, not a wellness building block.
TACT and TACT2: why the trials seem to contradict each other
Now to the heart of the controversy. Often either only the positive trial is cited or only the negative one. A complete picture only emerges when you lay both side by side, and this comparison is surprisingly instructive.
Post-infarction patients aged 50 and over received 40 infusions of an EDTA solution or placebo. The combined primary endpoint occurred in 26 percent instead of 30 percent, hazard ratio 0.82. A statistically borderline benefit, no effect on overall mortality. The authors themselves qualify that a large share of this difference fell on revascularizations, that is on procedures on the coronary arteries, not on deaths. What was used, by the way, was disodium EDTA, infused slowly under trial conditions.
What this means for you: A weak, just barely significant signal. On its own it is not enough to recommend EDTA as routine. But it was not nothing either.
DOI: 10.1001/jama.2013.2107In the pre-specified diabetic subgroup, the signal was strikingly strong. The primary endpoint was 25 percent instead of 38 percent, hazard ratio 0.59, with a number needed to treat of 6.5. In non-diabetics there was no effect.
What this means for you: In diabetics the effect was strong enough to trigger its own confirmatory trial. But subgroup findings always have to be read with caution, they can be real or coincidental. The observed reduction in overall mortality lost its statistical significance after correction for multiple testing.
DOI: 10.1161/CIRCOUTCOMES.113.000663The confirmation attempt. Diabetics with a prior infarction, EDTA versus placebo. The primary endpoint was 35.6 percent instead of 35.7 percent, adjusted hazard ratio 0.93, not significant. Notably: blood lead fell effectively from 9.03 to 3.46 micrograms per liter, the cardiac outcome improved nonetheless not at all.
What this means for you: An honest negative finding. EDTA lowered the lead measurably, without repeating the clinical benefit of the first trial. This does not support routine use.
DOI: 10.1001/jama.2024.11463The accompanying high-dose multivitamin and mineral arm of TACT2 was likewise negative. Primary endpoint 35 versus 35 percent, hazard ratio 0.99. Even the combination with EDTA brought no significant additional benefit.
What this means for you: The obvious hope that high-dose vitamins would amplify the effect was not confirmed. On the contrary, according to the authors there was a numerically higher rate of heart attacks, strokes and cardiovascular deaths in the vitamin group. This difference was not statistically confirmed, but it is a good reason not to regard high-dose multi-preparations as a harmless add-on. That too belongs to the honest balance sheet.
DOI: 10.1001/jamainternmed.2024.8408The summarizing bird's-eye view, a Cochrane synthesis of all RCTs on EDTA for atherosclerotic vascular disease. No proven difference in overall mortality, heart attack or stroke, no cluster of serious side effects. Important for the classification: the authors themselves rate the certainty of the individual results, assessed with GRADE, as low to very low. That is precisely why their conclusion is that the data is sufficient neither for proof of efficacy nor for proof of the opposite.
What this means for you: From the overall view, the data is currently not sufficient for a routine benefit. This is the sober balance sheet, and it deserves respect.
DOI: 10.1002/14651858.CD002785.pub2The honest middle ground that emerges from this
Why was TACT positive and TACT2 negative? The most plausible reading is surprisingly simple. The population's lead burden has fallen over the years. In TACT2, the baseline blood lead was only around 9 micrograms per liter. Where there is little lead, lowering lead can achieve little. The benefit would therefore lie where a relevant body lead burden still exists.
This is an interpretation, not a proven fact. The trial authors did not prove it. But it fits the findings together without contradiction: EDTA would therefore not be a heart medication for every diabetic, but at most a tightly indicated building block in cases of proven lead burden. What matters is not the agent, but the right indication.
Read this way, the polarization of the internet debate becomes easier to understand. Whoever declares EDTA an artery cleaner for everyone passes over the negative findings. Whoever dismisses it wholesale as ineffective passes over the subgroup and lead logic. Both readings fall short for me, without my claiming to know the final answer. My position is: without prior diagnostics, an EDTA infusion is blind activism, with a proven lead burden it could be a closely monitored building block, and whether it protects the heart is not proven by the current data.
EDTA is not made for mercury
A common misunderstanding: people expect EDTA to pull "all toxins" out of the body, including mercury out of the brain. According to current pharmacological knowledge, EDTA barely reaches the brain and is not considered a suitable chelating agent for mercury. A review of the sulfur-containing chelating agents names DMSA as the recommended agent for lead poisoning and organic mercury, and DMPS for acute poisoning with inorganic mercury salts (Bjørklund 2019). Both are likewise prescription-only substances with side effects of their own and only sensible after medical diagnostics. Every chelating agent has its metal and its site of action. Whoever confuses this builds up false expectations.
You will find the full comparison of all chelating agents, including DMPS, in the heavy metals pillar. The oral mercury chelator in detail is in the separate article on DMSA, the oral chelating agent. Here just the rule of thumb: EDTA for lead and blood vessels, DMSA or DMPS for mercury. Which test even reveals a relevant burden in the first place is clarified by the DMPS provocation test before any treatment decision.
What EDTA takes from you at the same time: the mineral price
EDTA is non-specific. It does not only grab the target metal, but also binds essential trace elements, above all zinc, and can take manganese and other minerals along with it. This is not a killer argument that makes the therapy impossible. But it is a detail to be taken seriously, one that often falls short in the public discussion around EDTA, sometimes because it gets swept under the table, sometimes because it gets blown up into a knockout argument. It matters to me neither to skip it nor to dramatize it.
The CDC report explicitly states that chelating agents increase the excretion of other heavy metals and minerals such as zinc. Viewed through the lifestyle and functional lens, the mineral loss is therefore above all a monitoring issue. Without checking the levels and without targeted replacement, a cycle could do more harm than good. With regular measurement and replenishment it can be controlled. That is why an accompanying mineral monitoring belongs to every serious EDTA therapy, not as an add-on, but as a fixed component.
The details on mineral loss, further risks and how to keep them in view, I go deeper into in the separate article on side effects, risks and mineral loss. How a complete treatment cycle actually proceeds, from preparation to follow-up monitoring, is in the article on the course of chelation therapy.
What is proven by studies: lead is a real vascular risk factor, EDTA reliably lowers blood lead, and a routine benefit for heart health is, according to the current evidence, not sufficiently proven. That is the scientific basis, and I do not keep the negative TACT2 finding quiet.
Clinically, I therefore place EDTA very narrowly. Not as a heart cure for everyone who worries about their arteries. But at most as one building block in people with a proven, relevant lead burden, with the safer salt, with monitoring, and always only after diagnostics. Conventional medicine does a great deal right and important in cardiology. What can be added in an integrative way is the question of the lead burden, which simply does not appear in the standard check. That is an additional layer, not a replacement.
None of this replaces guideline-based treatment
One sentence that matters to me: blood pressure medication, statins, platelet inhibitors and cardiological follow-up remain the basis after a heart attack. Please do not stop any prescribed medication and do not postpone any cardiological workup because you are looking into lead. The question of the lead burden is an additional layer, not an exchange for the existing therapy.
And with acute symptoms, the emergency number comes first. With chest pain, shortness of breath, cold sweats or new, unfamiliar symptoms, you call 112 in Germany, or your local emergency number. Not the question about heavy metals, and not an appointment at any practice.
Evidence overview: what we know and what we do not
| Statement | Evidence | Limitation |
|---|---|---|
| Low lead increases cardiovascular death risk | Two large cohorts | Association, not proof of individual causality |
| Lead harms vessels through NO and oxidative stress | Review + animal/cell model | Mechanistically plausible, human data limited |
| EDTA dissolves arterial calcium | Not supported | Myth, the pathway is lead removal, not de-calcification |
| EDTA lowers blood lead measurably | RCT (TACT2) | Lowering proven, no clinical cardiac benefit from it |
| EDTA cardiac benefit after infarction | 1 positive RCT, 1 negative | TACT positive, TACT2 negative, Cochrane insufficient |
| Diabetics benefit more | Subgroup, not confirmed | TACT subgroup strong, TACT2 could not replicate it |
| Wrong salt (Na₂EDTA) is life-threatening | CDC case series | Three documented deaths from hypocalcemia |
| EDTA also binds zinc and minerals | Authority document (CDC) | Zinc and mineral loss is described in the CDC report, extent and consequences differ individually. Monitoring and targeted replacement therefore belong to every cycle. |
| EDTA is meant to work against mercury in the brain | Not supported | Barely crosses the blood-brain barrier, use DMSA/DMPS |
| An EDTA infusion is a low-risk routine building block | Not supported | Prescription-only medicine, no authorization for use on the vascular system. Kidney burden, electrolyte shifts and interactions are possible. |
Frequently asked questions about EDTA chelation therapy
Does EDTA dissolve calcium out of the arteries?
No. The popular idea that EDTA binds calcium and therefore de-calcifies plaques is a mechanistically false shortcut. The plausible pathway of action is the removal of lead, which can disrupt vascular function through oxidative stress and reduced nitric oxide availability. EDTA binds metal, it does not melt away calcification.
What is the difference between CaNa₂EDTA and Na₂EDTA?
Calcium disodium EDTA (CaNa₂EDTA) already carries calcium and is considered the safer salt for lead elimination. Disodium EDTA (Na₂EDTA) abruptly binds blood calcium and can trigger life-threatening hypocalcemia. The CDC documented three deaths linked to hypocalcemia during chelation therapy. But safety does not hang on the letter alone, it hangs just as much on infusion rate, diagnostics and monitoring. When in doubt, ask which salt is being used.
Why was TACT positive and TACT2 negative?
TACT showed a weak benefit in 2013, and a strong one in the diabetic subgroup. TACT2 could not confirm this in 2024. The most plausible reading: the population's lead burden has fallen, with a baseline of only around 9 micrograms per liter. Where there is little lead, lowering lead can achieve little. This is an interpretation, not a proven fact.
Does EDTA help against mercury?
Hardly. According to current pharmacological knowledge, EDTA barely reaches the brain and is not considered a suitable chelating agent for mercury. For mercury, DMSA or DMPS are discussed instead, both likewise prescription-only substances with side effects of their own and only sensible after medical diagnostics. Which route fits in an individual case is not decided by an article, but by findings and history.
What does EDTA take away from the body at the same time?
EDTA binds non-specifically and can also take along essential trace elements such as zinc and manganese. The CDC report explicitly states that chelating agents increase the excretion of other heavy metals and minerals such as zinc. Without monitoring and targeted replacement, this could do harm. That is why a mineral check is mandatory for every cycle.
Is a single EDTA infusion enough to get rid of lead?
No. The deep lead store sits in the bone. The dwell time there is reported as years to decades. Blood lead is only the tip. Several cycles mobilize it step by step, and the redistribution out of the bone must stay clinically in view. A single infusion is not a concept.
Is EDTA a heart cure for everyone?
No. The Cochrane synthesis concludes: insufficient evidence for a routine clinical benefit. The authors themselves rate the certainty of the individual results as low to very low. EDTA appears conceivable at most as a tightly indicated building block in cases of proven body lead burden, not as a blanket artery cure. Also important: EDTA infusion solutions are prescription-only medicines, and there is no marketing authorization for use on the vascular system.
How do I know whether I even have a relevant lead burden?
Without prior diagnostics, an EDTA infusion is blind activism. Blood lead shows the current burden but says little about the bone reservoir. The indication arises from exposure history, measured values and the clinical picture together. The interpretation of the provocation test is contested here and belongs in experienced hands.
Is EDTA chelation therapy dangerous?
Even with the right salt and the correct protocol, an EDTA infusion is not a risk-free procedure. It can burden the kidneys, shift the mineral balance, lower blood pressure and, if given too quickly, disturb the calcium level. In the large trials, no cluster of serious side effects appeared under trial conditions, but that only exonerates the trial protocol, not every application in practice. Care can lower the risk, it does not remove it. Impaired kidney function, pregnancy, breastfeeding and childhood are separate reservations that need to be clarified beforehand.
Is the EDTA in the blood tube the same as the therapy?
It is the same substance name, but a completely different context. In the laboratory blood tube, a small amount of EDTA only prevents the sample from clotting. Chelation therapy is a deliberately dosed infusion to bind metal in the body. So searching for "EDTA blood tube" leads into a completely different area.
Read on in the heavy metals cluster
This article goes deep into a single question: EDTA for lead and blood vessels. You will find the big-picture context and the neighboring topics here.
Heavy metals: the overview
All metals, diagnostics and the full chelator comparison
PillarLead poisoning
Where the lead comes from and how it shows itself
Course of chelation therapy
How a treatment cycle actually proceeds
Side effects & risks
Mineral loss and risks in detail
DMSA in detail
The oral chelator in contrast to EDTA
DMPS provocation test
Diagnostics before any treatment decision
Sources
All studies checked by cross-verification (PubMed plus DOI URL plus abstract match). Tier marker per source. The human evidence here is solid (four RCTs, one Cochrane synthesis, two large cohorts), the mechanism is review- and animal-model-supported and labeled accordingly. Where a statement is only clinical observation or physiological reasoning, that is said in the text.
- Lamas GA, Goertz C, Boineau R, et al. Effect of disodium EDTA chelation regimen on cardiovascular events in patients with previous myocardial infarction: the TACT randomized trial. JAMA. 2013;309(12):1241-50. DOI: 10.1001/jama.2013.2107 [RCT, n=1708]
- Escolar E, Lamas GA, Mark DB, et al. The effect of an EDTA-based chelation regimen on patients with diabetes mellitus and prior myocardial infarction in TACT. Circ Cardiovasc Qual Outcomes. 2014;7(1):15-24. DOI: 10.1161/CIRCOUTCOMES.113.000663 [RCT subgroup, n=633]
- Lamas GA, Anstrom KJ, Navas-Acien A, et al. Edetate Disodium-Based Chelation for Patients With a Previous Myocardial Infarction and Diabetes: TACT2 Randomized Clinical Trial. JAMA. 2024;332(10):794-803. DOI: 10.1001/jama.2024.11463 [RCT, n=959]
- Ujueta F, Lamas GA, Anstrom KJ, et al. Multivitamins After Myocardial Infarction in Patients With Diabetes: A Randomized Clinical Trial. JAMA Intern Med. 2025;185(5):540-548. DOI: 10.1001/jamainternmed.2024.8408 [RCT, n=1000]
- Villarruz-Sulit MV, Forster R, Dans AL, Tan FN, Sulit DV. Chelation therapy for atherosclerotic cardiovascular disease. Cochrane Database Syst Rev. 2020;5(5):CD002785. DOI: 10.1002/14651858.CD002785.pub2 [Systematic review, k=5, n=1993]
- Menke A, Muntner P, Batuman V, Silbergeld EK, Guallar E. Blood lead below 0.48 micromol/L (10 microg/dL) and mortality among US adults. Circulation. 2006;114(13):1388-94. DOI: 10.1161/CIRCULATIONAHA.106.628321 [Cohort, n=13,946]
- Lanphear BP, Rauch S, Auinger P, Allen RW, Hornung RW. Low-level lead exposure and mortality in US adults: a population-based cohort study. Lancet Public Health. 2018;3(4):e177-e184. DOI: 10.1016/S2468-2667(18)30025-2 [Cohort, n=14,289]
- Centers for Disease Control and Prevention. Deaths associated with hypocalcemia from chelation therapy, Texas, Pennsylvania, and Oregon, 2003-2005. MMWR Morb Mortal Wkly Rep. 2006;55(8):204-7. PMID: 16511441 [Authority document, case series n=3]
- Vaziri ND. Mechanisms of lead-induced hypertension and cardiovascular disease. Am J Physiol Heart Circ Physiol. 2008;295(2):H454-65. DOI: 10.1152/ajpheart.00158.2008 [Mechanism review]
- Caetano ES, Mattioli SV, Silva ML, et al. Sildenafil attenuates oxidative stress and endothelial dysfunction in lead-induced hypertension. Basic Clin Pharmacol Toxicol. 2023;133(2):142-155. DOI: 10.1111/bcpt.13904 [In vivo rat + in vitro HUVEC]
- Diaz D, Fonseca V, Aude YW, Lamas GA. Chelation therapy to prevent diabetes-associated cardiovascular events. Curr Opin Endocrinol Diabetes Obes. 2018;25(4):258-266. DOI: 10.1097/MED.0000000000000419 [Narrative review]
- Peguero JG, Arenas I, Lamas GA. Chelation therapy and cardiovascular disease: connecting scientific silos to benefit cardiac patients. Trends Cardiovasc Med. 2014;24(6):232-40. DOI: 10.1016/j.tcm.2014.06.002 [Narrative review]
- Apostoli P, Corulli A, Metra M, Dei Cas L. [Lead and cardiopathy]. Med Lav. 2004;95(2):124-32. PMID: 15218744 [Mechanism review]
- Brito JA, McNeill FE, Stronach I, Webber CE, Wells S, Richard N, Chettle DR. Longitudinal changes in bone lead concentration: implications for modelling of human bone lead metabolism. J Environ Monit. 2001;3(4):343-51. DOI: 10.1039/b101493p PMID: 11523432 [Longitudinal study, n=327 re-measured]
- Bjørklund G, Crisponi G, Nurchi VM, Cappai R, Buha Djordjevic A, Aaseth J. A review on coordination properties of thiol-containing chelating agents towards mercury, cadmium, and lead. Molecules. 2019;24(18):3247. DOI: 10.3390/molecules24183247 PMID: 31489907 [Review of chelating agents]